Globus Medical Q3 net sales $625.7M (+63% YoY), raises FY24 revenue and EPS guidance

GLOBUS MEDICAL INC

2024-Q3 EPS reported $0.56 revenue$1,862,062,000

Worldwide net sales $625.7M, up 63.1% YoY, driven by NuVasive addition and higher spine/enabling tech sales.
GAAP diluted EPS $0.38 (vs $0.01 in Q3 2023); non-GAAP diluted EPS $0.83 (vs $0.57, +45.2%).
Non-GAAP adjusted EBITDA $193.7M, or 31.0% of net sales.
Raised FY2024 guidance: revenue $2.49-$2.50B; non-GAAP diluted EPS $2.90-$3.00 (includes $0.09 change in treatment of IPR&D).
Net cash from operations $203.7M; non-GAAP free cash flow $161.7M in Q3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.